{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T17:04:34Z","timestamp":1779987874578,"version":"3.53.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1S","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Acute kidney injury (AKI) in a patient with cirrhosis has high short-term mortality. Midodrine has shown promising results in the treatment of AKI-hepatorenal syndrome (HRS-AKI).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Aims<\/jats:title>\n            <jats:p>To compare midodrine and albumin versus albumin alone for the secondary prophylaxis of HRS-AKI.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and method<\/jats:title>\n            <jats:p>Open labeled, nonrandomized, pilot study. Patients with a diagnosis of HRS-AKI were recruited after complete recovery. Patients were given midodrine daily (15 mg) and injection albumin infusion 20 g weekly in group-A (Gp-A) and injection albumin 20 g weekly with no midodrine in group-B (Gp-B). The primary endpoint was the recurrence of AKI-HRS, and the secondary endpoint was ascites tap in 2-month period.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 42 patients were enrolled in Gp-A, <jats:italic toggle=\"yes\">n<\/jats:italic> = 22, and Gp-B, <jats:italic toggle=\"yes\">n<\/jats:italic> = 20. There was no significant difference between the groups (Gp-A vs. Gp-B) in terms of age, model stage liver disease, Child\u2013Turcotte\u2013Pugh score and serum creatinine at inclusion (1.27 \u00b1 0.1 vs. 1.22 \u00b1 0.2 mg\/dL). During follow up ten patients (50%) in Gp-B and four patients (18%) in Gp-A develop HRS-AKI (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.04). The mean number of ascites tap was significantly higher in Gp-B compared to Gp-A (2.6 \u00b1 0.5 vs. 1.9 \u00b1 0.5) in 2 months. There was a significant increase in mean arterial pressure in Gp-A compared to Gp-B on days 7, 15, 30, 45 and 60. There was a significant difference in mean arterial pressure at day 7 in patients who developed HRS-AKI versus those who did not develop HRS-AKI [(<jats:italic toggle=\"yes\">n<\/jats:italic> = 14, 65.5 \u00b1 5.5) vs. (<jats:italic toggle=\"yes\">n<\/jats:italic> = 28,74.6 \u00b1 9.2 mm Hg), <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.02].<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Midodrine along with albumin infusion, is helpful in the secondary prophylaxis of HRS-AKI and reduces the number of ascites tap. However, a large randomized study is required for further validation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/meg.0000000000002154","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T22:02:30Z","timestamp":1621980150000},"page":"e499-e504","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Midodrine and albumin versus albumin alone for the secondary prophylaxis of acute kidney injury in a patient with cirrhosis and ascites"],"prefix":"10.1097","volume":"33","author":[{"given":"Praveen","family":"Sharma","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Sir Ganga Ram Hospital, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Puri","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sir Ganga Ram Hospital, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Bansal","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sir Ganga Ram Hospital, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Singla","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sir Ganga Ram Hospital, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sir Ganga Ram Hospital, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil Anikhindi","family":"ShriHari","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sir Ganga Ram Hospital, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Arora","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sir Ganga Ram Hospital, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,5,21]]},"reference":[{"key":"R1-20240821","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/liv.13893","article-title":"Hepatorenal syndrome in the era of acute kidney injury.","volume":"38","author":"Sol\u00e9","year":"2018","journal-title":"Liver Int"},{"key":"R2-20240821","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1053\/j.gastro.2016.02.026","article-title":"Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1.","volume":"150","author":"Boyer","year":"2016","journal-title":"Gastroenterology"},{"key":"R3-20240821","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1053\/j.gastro.2008.02.014","article-title":"A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome.","volume":"134","author":"Sanyal","year":"2008","journal-title":"Gastroenterology"},{"key":"R4-20240821","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1053\/j.gastro.2008.02.024","article-title":"Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.","volume":"134","author":"Mart\u00edn-Llah\u00ed","year":"2008","journal-title":"Gastroenterology"},{"key":"R5-20240821","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1002\/hep.22605","article-title":"Acute kidney injury in cirrhosis.","volume":"48","author":"Garcia-Tsao","year":"2008","journal-title":"Hepatology"},{"key":"R6-20240821","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1080\/03007995.2018.1552575","article-title":"Terlipressin for the treatment of hepatorenal syndrome: an overview of current evidence.","volume":"35","author":"Zhang","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"R7-20240821","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/17474124.2018.1417034","article-title":"Hepatorenal syndrome: the clinical impact of vasoactive therapy.","volume":"12","author":"Colle","year":"2018","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R8-20240821","first-page":"CD011532","article-title":"Terlipressin versus other vasoactive drugs for hepatorenal syndrome.","volume":"9","author":"Israelsen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R9-20240821","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/hep.510290629","article-title":"Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.","volume":"29","author":"Angeli","year":"1999","journal-title":"Hepatology"},{"key":"R10-20240821","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/j.1572-0241.2008.01828.x","article-title":"An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.","volume":"103","author":"Sharma","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R11-20240821","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jhep.2011.04.027","article-title":"Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study.","volume":"56","author":"Singh","year":"2012","journal-title":"J Hepatol"},{"key":"R12-20240821","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/ajg.2013.9","article-title":"Midodrine and clonidine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study.","volume":"108","author":"Singh","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"R13-20240821","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/hep.27709","article-title":"Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial.","volume":"62","author":"Cavallin","year":"2015","journal-title":"Hepatology"},{"key":"R14-20240821","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.jhep.2014.12.029","article-title":"Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites.","volume":"62","author":"Angeli","year":"2015","journal-title":"J Hepatol"},{"key":"R15-20240821","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/liv.12528","article-title":"Albumin infusion improves renal blood flow autoregulation in patients with acute decompensation of cirrhosis and acute kidney injury.","volume":"35","author":"Garcia-Martinez","year":"2015","journal-title":"Liver Int"},{"key":"R16-20240821","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.3748\/wjg.v12.i9.1403","article-title":"Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial.","volume":"12","author":"Romanelli","year":"2006","journal-title":"World J Gastroenterol"},{"key":"R17-20240821","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/S0140-6736(18)30840-7","article-title":"Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial.","volume":"391","author":"Caraceni","year":"2018","journal-title":"Lancet"},{"key":"R18-20240821","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/hep.510280407","article-title":"Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.","volume":"28","author":"Angeli","year":"1998","journal-title":"Hepatology"},{"key":"R19-20240821","first-page":"e45","article-title":"The role of midodrine for hypotension outside of the intensive care unit.","volume":"24","author":"Gutman","year":"2017","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"R20-20240821","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/hep.26359","article-title":"Introduction to the revised American Association for the Study of liver diseases practice guideline management of adult patients with ascites due to cirrhosis 2012.","volume":"57","author":"Runyon","year":"2013","journal-title":"Hepatology"},{"key":"R21-20240821","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jhep.2006.09.012","article-title":"Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites.","volume":"46","author":"Kalambokis","year":"2007","journal-title":"J Hepatol"},{"key":"R22-20240821","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.jhep.2018.08.006","article-title":"Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial.","volume":"69","author":"Sol\u00e0","year":"2018","journal-title":"J Hepatol"},{"key":"R23-20240821","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.dld.2008.09.014","article-title":"Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: a case-control study.","volume":"41","author":"Alessandria","year":"2009","journal-title":"Dig Liver Dis"},{"key":"R24-20240821","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jceh.2014.08.007","article-title":"Role of human albumin in the management of complications of liver cirrhosis.","volume":"4","author":"Bernardi","year":"2014","journal-title":"J Clin Exp Hepatol"},{"key":"R25-20240821","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/MEG.0000000000001594","article-title":"Effect of alpha agonists on the prevention of postparacentesis circulatory dysfunction in patients with refractory or recurrent ascites: a meta-analysis.","volume":"32","author":"Tripathy","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"}],"container-title":["European Journal of Gastroenterology &amp; Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000002154","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T22:04:26Z","timestamp":1724364266000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000002154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,21]]},"references-count":25,"journal-issue":{"issue":"1S","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/meg.0000000000002154","relation":{},"ISSN":["0954-691X"],"issn-type":[{"value":"0954-691X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,21]]}}}